Transcriptome data‐based status of PI3K/AKT/mTOR pathway indicates heterogeneity and immune modulation in patients with pancreatic ductal adenocarcinoma
The Journal of Gene Medicine · 2024
DOI: 10.1002/jgm.3570 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Journal of Gene Medicine, 2024. Verfasst von Peng Xie und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgery, School of Medicine, Southeast University, Nanjing, China. Hauptthemen laut MEDLINE: Carcinoma, Pancreatic Ductal, Pancreatic Neoplasms. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 30 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Natural Science Foundation of Jiangsu Province, Program of Medical Innovation Team and Leading Medical Talents in Jiangsu Province.
Abstract (Originalsprache)
Background
Pancreatic ductal adenocarcinoma (PDAC) is a highly lethal cancer with limited treatment options. The PI3K/AKT/mTOR pathway is commonly activated in PDAC and plays a critical role in its progression. Methods and Results In this study, the effect of taselisib (a selective PI3K inhibitor) on PDAC cell proliferation was investigated, and a significant decrease in viability was observed with increasing concentrations of taselisib. Differential analysis on samples from the Genotype–Tissue Expression and The Cancer Genome Atlas databases revealed 24 dysregulated PI3K/AKT/mTOR pathway‐related genes (PRGs). Unsupervised clustering‐based analysis of transcriptome cohorts revealed two clusters with high consistency between RNA‐seq and microarray cohorts. Cluster B had higher enrichment of immune cells, particularly CD8 + T cells, and lower levels of immunosuppressive Treg cells. Moreover, we investigated the relationship between drug sensitivity and different clusters and found that cluster A had a better response to PI3K/AKT/mTOR pathway‐related inhibitors and chemotherapy. Finally, cluster A exhibited significant activation of PI3K/AKT/mTOR and related oncogenic pathways, contributing to poor prognosis. The study also developed a risk score based on the expression profiles of PRGs and machine learning, which showed a significant increase in overall survival time among patients in the low‐risk group. Importantly, the PI3K/AKT/mTOR pathway could be used to better predict individual risk scores, as evidenced by stratified survival analysis.
Conclusions
These findings suggest that targeting the PI3K/AKT/mTOR pathway may have therapeutic potential in PDAC, and distinct pathway states, immune modulation and tumor microenvironments have prognostic value.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Surgery, School of Medicine, Southeast University, Nanjing, China.
- Department of Hepato-Pancreatico-Biliary Surgery, Zhongda Hospital Southeast University, Nanjing, China.
Förderung
- National Natural Science Foundation of China
- Natural Science Foundation of Jiangsu Province
- Program of Medical Innovation Team and Leading Medical Talents in Jiangsu Province
Zitieren
APA
Xie, P., Tan, S. Y., Li, H. F., Tang, H. D., & Zhou, J. H. (2024). Transcriptome data‐based status of PI3K/AKT/mTOR pathway indicates heterogeneity and immune modulation in patients with pancreatic ductal adenocarcinoma. The Journal of Gene Medicine. https://doi.org/10.1002/jgm.3570
Vancouver
Xie P, Tan SY, Li HF, Tang HD, Zhou JH. Transcriptome data‐based status of PI3K/AKT/mTOR pathway indicates heterogeneity and immune modulation in patients with pancreatic ductal adenocarcinoma. The Journal of Gene Medicine. 2024. doi:10.1002/jgm.3570
BibTeX
@article{Xie2024,
author = {Xie, Peng and Tan, Si-Yuan and Li, Hai-Feng and Tang, Hao-Dong and Zhou, Jia-Hua},
title = {Transcriptome data‐based status of PI3K/AKT/mTOR pathway indicates heterogeneity and immune modulation in patients with pancreatic ductal adenocarcinoma},
journal = {The Journal of Gene Medicine},
year = {2024},
doi = {10.1002/jgm.3570}
}
EUVIMED